Thermo Fisher Scientific Inc. Earnings Recaps
Thermo Fisher’s shares fell 1.6% after earnings, a roughly flat reaction. Revenue and adjusted EPS grew, but performance was uneven across end markets: academic and government revenue was flat, while diagnostics and healthcare grew at a low-single-digit rate.
Key takeaways
- Q3 revenue increased 9% to $12.14 billion; adjusted EPS rose 15% to $6.68.
- Adjusted operating income grew 15% to $2.97 billion, and adjusted operating margin expanded 120 basis points to 24.5%.
- Pharma and biotech and industrial and applied each delivered high-single-digit growth; academic and government revenue was flat.
- Diagnostics and healthcare grew low single digits, with transplant diagnostics cited as a source of strength.
- Management said improved end-market conditions seen in Q2 continued in Q3; the excerpt provides no updated full-year outlook.
Thermo Fisher shares rose 7.9% following a quarter that beat expectations on revenue growth, margin expansion, and innovation-driven execution across key end markets.
Key takeaways
- Revenue increased 10% to $11.99 billion, driven by broad strength across Pharma & Biotech, Academic & Government, Industrial & Applied, and Diagnostics & Health Care segments.
- Adjusted operating income grew 15% to $2.73 billion, with operating margins expanding by 90 basis points to 22.8%.
- Adjusted EPS rose 13% to $6.03 per share, reflecting both top-line strength and margin leverage.
- Continued high-impact innovation including new Orbitrap mass spectrometry platforms and AI-enhanced software contributed to commercial momentum and customer adoption.
- Strategic investments such as opening a bioprocess design center and collaboration in population health research underscore ongoing commitments to growth and customer engagement.
Thermo Fisher delivered a robust Q1 with 6% revenue growth to $11.01 billion, driven by strength in biotech and pharma markets, while maintaining disciplined margins and expanding innovative offerings.
Key takeaways
- Revenue increased 6% to $11.01 billion; adjusted EPS up 6% to $5.44, supported by a 21.8% operating margin.
- Pharma and biotech markets grew mid-single-digit, led by bioproduction, clinical research, and safety channels.
- Launches included advanced cryo-EM and mass spectrometry solutions, reinforcing industry leadership and customer value.
- Strategic collaborations with NVIDIA and SHL Medical enhance AI-driven workflows and manufacturing capabilities.
- End markets are expected to remain resilient amid macroeconomic uncertainties and ongoing innovation efforts.
Thermo Fisher Scientific demonstrated solid operational performance in Q3 2025, achieving a 5% revenue increase to $11.12 billion and raising full-year guidance due to strong growth in its bioproduction and analytical instruments segments.
Key takeaways
- Adjusted operating income rose 9% to $2.59 billion, while adjusted EPS grew 10% to $5.79 per share.
- Pharma and biotech revenue maintained mid-single-digit growth, supported by strong contributions from bioproduction and analytical instruments.
- Diagnostics and Healthcare revenue showed improvement, though it remained down low single digits due to challenging conditions in China.
- Continued innovation highlighted by FDA approvals for clinical genomic tests and new launches in proteomics and electron microscopy.
- Strengthened customer relationships through strategic collaborations, including a notable partnership with OpenAI.